Natural‐source d‐α‐tocopheryl acetate inhibits oxidant stress and modulates atopic asthma in humans in vivo
- 22 March 2012
- Vol. 67 (5), 676-682
- https://doi.org/10.1111/j.1398-9995.2012.02810.x
Abstract
Background Asthma is associated with oxidant stress and diminished antioxidant defenses. Yet, the mechanistic role of oxidant stress and antioxidant supplementation in human asthmatics remains uncertain. We determined the effect of high doses of the antioxidant natural‐source d‐α‐tocopheryl acetate for 16 weeks on allergen‐induced airway oxidant stress, inflammation, and bronchial responsiveness to methacholine and allergen in atopic asthmatics in vivo. Methods Thirty‐three mild atopic asthmatics underwent bronchoscopy with baseline bronchoalveolar lavage and segmental allergen challenge. The allergen‐challenged airway was lavaged 24 h later. At least 3 weeks later, patients underwent inhaled challenges with methacholine and specific allergen. Volunteers took 1500 IU of natural‐source d‐α‐tocopheryl acetate daily for at least 16 weeks. At the end of the treatment, the two bronchoscopies and inhaled methacholine and allergen challenges were repeated. F2‐isoprostanes, specific markers of oxidant stress, and selected Th1 and Th2 cytokines were analyzed in the lavage fluid. Results Following supplementation of natural‐source d‐α‐tocopheryl acetate, plasma concentrations of α‐tocopherol increased and γ‐tocopherol decreased. Both baseline and allergen‐induced F2‐isoprostanes significantly decreased, providing biochemical evidence for an antioxidant effect. Natural‐source d‐α‐tocopheryl acetate reduced allergen‐provoked concentrations of interleukin 3 and interleukin 4 and augmented levels of interleukin 12 in bronchoalveolar lavage fluid. Natural‐source d‐α‐tocopheryl acetate improved airway responsiveness to methacholine but did not alter airway reactivity to specific allergen. Conclusions Inhibition of oxidant stress by natural‐source d‐α‐tocopheryl acetate modulates allergic inflammation and airway hyperresponsiveness in human atopic asthmatics in vivo. These results need to be confirmed by a randomized placebo‐controlled trial.This publication has 35 references indexed in Scilit:
- Eosinophil and neutrophil extracellular DNA traps in human allergic asthmatic airwaysJournal of Allergy and Clinical Immunology, 2011
- T-helper Type 2–driven Inflammation Defines Major Subphenotypes of AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Long-Term Use of Supplemental Multivitamins, Vitamin C, Vitamin E, and Folate Does Not Reduce the Risk of Lung CancerAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Effects of Random Allocation to Vitamin E Supplementation on the Occurrence of Venous ThromboembolismCirculation, 2007
- Effect of an NK1/NK2 Receptor Antagonist on Airway Responses and Inflammation to Allergen in AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Vitamin E supplements in asthma: a parallel group randomised placebo controlled trialThorax, 2004
- Polymorphisms at the glutathione S‐transferase, GSTP1 locus: a novel mechanism for susceptibility and development of atopic airway inflammationAllergy, 2000
- Practice parameters for allergy diagnostic testing. Joint Task Force on Practice Parameters for the Diagnosis and Treatment of Asthma. The American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology.1995
- T Cells and Cytokines in Bronchoalveolar Lavage Fluid after Segmental Allergen Provocation in Atopic AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 1995
- Oral α-Tocopherol Supplements Decrease Plasma γ-Tocopherol Levels in HumansJournal of Nutrition, 1985